We are live on ! Find out more
EVGN icon

Evogene
EVGN

22 hedge funds and large institutions have $39.3M invested in Evogene in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

22% more funds holding

Funds holding: 18 → 22 (+4)

0.34% more ownership

Funds ownership: 29.89% → 30.24% (+0.34%)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

22% less capital invested

Capital invested by funds: $50.1M → $39.3M (-$10.9M)

Holders
22
Holders Change
+4
Holders Change %
+22.22%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$765K
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$572K
3
MCM
Moon Capital Management
New York
+$323K
4
Bank of America
Bank of America
North Carolina
+$211K
5
Jane Street
Jane Street
New York
+$168K

Top Sellers

Rank Fund Capital Flow
1
WRF
Waddell & Reed Financial
Kansas
-$936K
2
Goldman Sachs
Goldman Sachs
New York
-$577K
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$489K
4
Citigroup
Citigroup
New York
-$18.2K
5
SWM
Stockman Wealth Management
Montana
-$3.72K

EVGN Hedge Fund Activity: Q4 2016 in Review

22 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2016, worth a combined $39.3M — down 22% from $50.1M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EVGN positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was UBS Group, adding an estimated $765K. The largest seller was Waddell & Reed Financial, cutting an estimated $936K.

  • 22 institutional investors held Evogene (EVGN) as of Q4 2016, up from 18 in Q3 2016.
  • Funds reported $39.3M of Evogene stock for Q4 2016, down 22% quarter-over-quarter.
  • 5 funds opened new Evogene positions in Q4 2016 and 1 closed out, a net change of +4 holders.
  • The largest Evogene buyer in Q4 2016 was UBS Group, an estimated $765K added.
  • The largest Evogene seller in Q4 2016 was Waddell & Reed Financial, an estimated $936K sold.

Based on aggregated 13F filings for Q4 2016.